New strategies for the treatment of neurotoxic side effects in CAR-T cell therapy
DOI ： ： 10.3872/j.issn.1007-385x.2019.06.001
- VernacularTitle:CAR-T细胞治疗的神经毒性副反应处理新策略
- Author:
LIU Zhaonan
1
,
2
,
3
;
HAN Weidong
4
;
JIANG Jingting
1
,
2
,
3
Author Information
1. (
2. Department of Tumor Biological Treatment, the Third Affiliated Hospital of Soochow University, Changzhou 213003, Jiangsu, China;
3. Institute of Cell Therapy, Soochow University
4. Institute of Basic Medicine, General Hospital of PLA
- Publication Type:Journal Article
- Keywords:
chimeric antigen receptor modified T (CAR-T) cell;
neurotoxicity;
CAR-T cell relevant encephalopathy syndrome (CRES);
coping strategies
- From:
Chinese Journal of Cancer Biotherapy
2019;26(6):617-622
- CountryChina
- Language:Chinese
-
Abstract:
Chimeric antigen receptor modified T (CAR-T) cell therapy is one of the important methods of tumor immunotherapy. The targeting, killing, proliferation and persistence of CAR-T cells are significantly enhanced than that of conventional T cells.After continuous improvement and evolution, CAR-T cell treatment has achieved excellent progress in hematological tumors and has received extensive attention. However, neurotoxicity arising from the treatment, also known as CAR-T cell relevant encephalopathy syndrome (CRES), has affected its clinical application. Exploring the pathogenesis of CRES and high-risk factors, and finding appropriate strategies is therefore critical for the prevention and treatment of CRES. Here, we take CD19-CAR-T cell treatment as example to review the symptoms and pathogenesis of CRES, discuss high-risk factors as well as coping strategies, in an effort to provide a reference for clinical treatment.
- Full text:20190601.pdf
